Summary

In a custom synthesis project, approval of a gram-scale sample only demonstrates that the target compound can be produced under specific laboratory conditions. It does not prove that the same quality can be reproduced consistently at the kilogram scale, in validation batches, or in commercial batches.

As production scale increases, raw material sources, equipment configuration, mixing efficiency, addition time, heat-transfer conditions, purification methods, drying processes, and packaging formats may all change. These changes may not cause an obvious reduction in target purity, but they can lead to increases in critical individual impurities, changes in isomer ratios, higher moisture content, different residual solvent profiles, or fluctuations in application performance.

Before moving from gram-scale samples to bulk procurement, five connected quality scale-up gates should be established: product identity and specification freeze, gram-scale sample and impurity baseline, kilogram-scale process replication, representative validation batches, and commercial batch release and change control. Each gate should generate traceable release evidence rather than relying on the result of a single sample test.

Why Custom Synthesis Should Not Move Directly from a Gram-Scale Sample to a Commercial Batch

The main difference between a laboratory sample and a commercial batch is not simply production volume.

Gram-scale samples are usually produced in small glassware, where reaction conditions are easier to observe and addition, heating and cooling, extraction, filtration, and purification can be adjusted precisely. When production moves to the kilogram scale or beyond, the following changes may occur:

• Addition times become longer, changing local reactant concentrations;
• Equipment heat-transfer and mixing efficiency differ from laboratory conditions;
• Laboratory column chromatography is replaced by crystallization, slurry washing, or other purification methods;
• Raw materials shift from small-pack research-grade materials to bulk supply specifications;
• Washing, filtration, and drying times increase;
• The material remains exposed to air or humidity for longer periods;
• Packaging changes from sample bottles to bags, drums, or other commercial formats.

A gram-scale sample is therefore only the starting point of the project. What must ultimately be verified is whether the target structure, impurity profile, and application performance can remain stable under conditions closer to commercial production.

How the Five Quality Scale-Up Gates Connect

These five gates are not simply production steps. They are five independent purchasing and quality decisions. If the evidence from the previous gate is insufficient, the project should not move forward based only on supplier assurances.

Gate 1: Freeze Product Identity, Specifications, and Analytical Methods

Product Name and CAS Number Alone Do Not Fully Define the Procurement Target

Custom synthesis inquiries often begin with the product name, CAS number, and target purity, but this information is not sufficient to fully describe the material being procured.

Specification confirmation should also include:

• Full chemical name;
• Structural formula;
• Molecular formula and molecular weight;
• Substitution position;
• Stereochemical configuration;
• Free form, salt form, hydrate, or solvate form;
• Whether positional isomers, geometric isomers, or enantiomers require control;
• The product’s specific role in the downstream reaction or material system.

Different structural forms may exist under the same general name. A CAS number can assist with substance identification, but it cannot replace confirmation of the structural formula, salt form, and isomeric form.

Break Down “Purity Requirements” into Critical Quality Attributes

“Purity not less than 99%” is generally not a complete acceptance specification for a custom synthesis project. The attributes that directly affect downstream reactions, formulations, or material performance must be identified according to the intended application.

Not every project requires all of these tests. Specifications should focus on quality attributes that genuinely affect the intended application, rather than including a large number of parameters that cannot be interpreted, measured consistently, or linked to performance.

Confirm Analytical Methods Before Sample Synthesis

The same batch may produce different results when tested using different columns, mobile phases, detection wavelengths, sample concentrations, or integration rules.

The following should be confirmed at the beginning of the project:

• Whether HPLC, GC, titration, or another assay method will be used;
• Whether reference standards are available for critical impurities;
• How unknown impurities will be integrated and reported;
• Whether the method can separate the target compound from critical isomers;
• Which methods will be used for moisture, residual solvents, and metals;
• Whether method comparison between the customer’s and supplier’s laboratories is required.

If the analytical method has not been aligned, both parties may report “passing” results while still reaching incorrect conclusions because the methods are not comparable.A structured fine chemical document review can further confirm whether specifications, COAs, TDSs, SDSs, impurity data, and analytical methods describe the same material.

Release Conditions for Gate 1

Before sample synthesis begins, the following should be completed at a minimum:

• Product identity confirmation;
• Structural form confirmation;
• Definition of critical quality attributes;
• Preliminary confirmation of analytical methods;
• Confirmation of gram-scale sample quantity;
• Confirmation of the target scale-up volume;
• Preliminary confirmation of packaging, storage, and destination requirements;
• Agreement on specification changes and project communication.

Gate 2: Gram-Scale Sample and Impurity Baseline

The Gram-Scale Sample Must Complete Three Types of Validation

The gram-scale sample stage is not only intended to prove that the target product can be synthesized. It must also confirm:

1. Whether the structure is correct;
2. Whether the quality meets the initial specification;
3. Whether the sample is suitable for the intended application.

Depending on structural complexity and risk, NMR, mass spectrometry, infrared spectroscopy, elemental analysis, optical rotation, chiral analysis, or other appropriate methods may be combined for structural confirmation.

For products with high isomer risk, multiple closely related impurities, or sensitive downstream applications, a single chromatographic purity result is generally insufficient to prove that the sample meets the requirements.

Establish an Impurity Baseline for Subsequent Comparison

After the gram-scale sample is approved, the quality characteristics of the batch should be retained rather than keeping only a single purity number from the COA.

Recommended records include:

• Original chromatograms;
• Main-peak retention time;
• Identified impurities and their relative levels;
• Location and proportion of major unknown impurities;
• Moisture and residual solvent data;
• Appearance, color, and physical form;
• Structural confirmation data;
• Route version corresponding to the sample;
• Sample batch number and production date.

These data form the impurity baseline used to compare subsequent kilogram-scale and validation batches.

If the scale-up batch has a total purity similar to the gram-scale sample but shows new unknown peaks, increased critical impurities, or changes in isomer ratio, it still requires reassessment and should not be released based only on total purity.

The Sample Must Be Validated under Real Application Conditions

Passing the supplier’s laboratory tests does not automatically mean that the sample is suitable for downstream use. The gram-scale sample should normally be evaluated under real or near-real application conditions, such as:

• Use in the next synthetic step;
• Formulation compatibility testing;
• Polymerization, curing, coating, or material preparation;
• Comparison of reaction yield and selectivity;
• Evaluation of dissolution, dispersion, color, or processing behavior;
• Assessment of whether trace impurities affect critical performance.

Application test results should be linked to the sample batch number. During subsequent procurement, it must be possible to confirm the relationship between the commercial batch and the sample that passed validation.

Sample Representativeness Should Be Classified by Level

Different sample sources can demonstrate different levels of evidence.

Approval of a gram-scale sample should not be treated as complete evidence that the sample represents future commercial production.

Release Conditions for Gate 2

Before moving to scale-up, confirm that:

• The structure has been verified using appropriate methods;
• The sample meets the preliminary specification;
• The sample has completed the intended application testing;
• The impurity baseline has been established;
• The sample batch number and route version are traceable;
• A reference sample has been retained in appropriate packaging;
• Critical items that must not be changed without evaluation during scale-up have been defined.

Gate 3: Kilogram-Scale Process Replication and Impurity Change Validation

The Purpose of Scale-Up Validation Is Process Replication, Not Simply Higher Output

The hundred-gram to kilogram-scale stage should identify which process variables directly affect final product quality.

Common variables include:

• Source and actual assay of critical raw materials;
• Order and rate of addition;
• Reaction temperature and temperature fluctuations;
• Agitation and mixing conditions;
• Reaction endpoint determination;
• Extraction, washing, and phase-separation processes;
• Concentration temperature and time;
• Crystallization solvent ratio;
• Cooling rate and aging time;
• Filtration and drying conditions;
• Reprocessing or repeated purification.

The supplier may retain exact charge ratios, precise process parameters, and proprietary operations as confidential business information, but it still needs to demonstrate that critical quality risks have been identified.

Compare Impurity Profiles after Scale-Up, Not Only Yield

A reduction in yield is usually easy to identify, while changes in impurity profile are more likely to be overlooked.

The kilogram-scale batch should be compared with the gram-scale sample for at least the following:

• Target-peak purity;
• Critical individual impurities;
• Newly appearing unknown impurities;
• Isomer ratio;
• Residual solvent types and levels;
• Moisture;
• Color or physical form;
• Number of purification cycles;
• Reprocessing or secondary treatment.

If kilogram-scale material requires multiple additional purification cycles to reach the gram-scale quality level, it is necessary to determine whether the process can still maintain acceptable cost, capacity, and lead time in commercial production.

Critical Raw Material Changes Must Be Included in the Scale-Up Assessment

The sample stage may use high-grade raw materials supplied in small packages, while larger-scale production requires raw materials available in stable bulk supply. Changes in raw material source may introduce new isomers, metals, salts, moisture, or other reactive impurities.

The scale-up stage should confirm:

• Whether critical starting materials have stable sources;
• Whether raw material specifications can support the target product quality;
• Whether single-source risk exists;
• Whether a change in critical raw material source requires reassessment;
• Whether catalysts, ligands, solvents, and purification materials can be supplied continuously;
• Whether raw material procurement time has been included in the project lead time.

What the Supplier May Keep Confidential and What It Still Needs to Provide

The purpose of procurement evaluation is not to obtain all supplier process secrets, but to obtain enough evidence to judge whether the required quality can be reproduced.

Release Conditions for Gate 3

Before entering representative validation-batch production, the following should be available:

• Scale-up batch records;
• Critical process parameters and their acceptable ranges;
• Comparison of impurity profiles between gram-scale and scale-up batches;
• Yield and production-cycle records;
• Deviation and reprocessing explanations;
• Critical raw material sources and specifications;
• Main equipment and purification methods expected for commercial production;
• The next-stage validation plan.

Gate 4: Representative Validation Batches, Consecutive Batches, and Packaging Suitability

Representative Validation Batches Should Closely Reflect Future Commercial Conditions

A representative validation batch is a batch produced under conditions as close as practical to future commercial production, including the site, equipment, raw materials, purification process, analytical methods, and packaging.

Its purpose is not to produce another larger laboratory sample, but to verify future supply conditions.

Confirm whether the validation batch uses:

• The planned commercial production site;
• The same or representative equipment type;
• Critical raw material grades intended for commercial supply;
• Planned purification and drying methods;
• Formal quality-control methods;
• Planned packaging materials and unit package weight.

If the validation batch still depends on manual operations, small-scale equipment, or laboratory column chromatography that cannot be reproduced commercially, the result has limited value for formal bulk procurement.

The Number of Consecutive Batches Should Be Based on Quality Risk

There is no single validation-batch number applicable to every custom synthesis project.

The decision should consider:

• Number of process steps and structural complexity;
• Difficulty of controlling critical impurities;
• Raw material batch variability;
• Sensitivity of the downstream application;
• Value of each procurement batch;
• Potential loss caused by quality failure;
• Time required for revalidation;
• Difficulty of changing suppliers.

Higher-risk projects normally require trend evaluation across multiple consecutive batches rather than reviewing only the best-performing batch. The specific number of batches should be defined in the project quality plan.

Batch Consistency Does Not Mean Every Result Must Be Identical

Batch consistency means that critical quality attributes remain within predefined, explainable, and controlled ranges. It does not mean that every analytical result must be exactly the same.

Consecutive batches may be compared for:

• Purity and assay;
• Critical individual impurities;
• Isomer ratio;
• Moisture;
• Residual solvents;
• Metal residues;
• Appearance and color;
• Particle size or bulk density;
• Application test results;
• Yield and production cycle.

Reporting only “Pass” or “Conforms” does not support trend analysis. Actual results should be retained for critical quality attributes wherever possible, and all batches should use the same methods and reporting rules.

Packaging Must Be Included in Validation

Commercial packaging may change the condition of the material during transportation and storage, so it should not be selected only after the commercial batch has already been produced.

Packaging validation should not only check whether the container remains intact. It should also confirm that moisture, appearance, seal condition, and critical quality attributes remain acceptable after transportation and storage.

Release Conditions for Gate 4

Before moving to commercial procurement, confirm that:

• The validation batch is representative of commercial production;
• Consecutive batch data remain within acceptable ranges;
• Critical impurities show no abnormal upward trend;
• Application test results are reproducible;
• Formal analytical methods are being executed consistently;
• Packaging and transportation conditions have been validated;
• The commercial batch specification has been frozen;
• Changes requiring notification have been defined.

Gate 5: Commercial Batch Release, Deviation Handling, and Change Control

Commercial Batches Must Be Released against the Same Specification Version

Formal purchase orders, quality agreements, specifications, and COAs should remain consistent.

Common problems include:

• Quotations, contracts, and COAs using different purity standards;
• Critical impurities being tested during the sample stage but no longer reported for commercial batches;
• Customer methods being used during validation but replaced by different methods during routine production;
• Samples and commercial batches being produced at different sites without reassessment;
• Original validation conclusions continuing to be used after a critical raw material change.

Commercial batch documentation should identify the applicable specification and analytical method versions. Revision records should be retained when specifications or methods change.

Changes Should Be Classified According to Their Potential Impact

Not every change requires complete revalidation, but changes that may affect product identity, impurity profile, or application performance should not be handled only as internal administrative records.

The definition of major and moderate changes should be agreed at the beginning of the project according to the characteristics of the product and process.

Deviation and Reprocessing Rules Should Be Agreed in Advance

When a commercial batch shows an abnormality, the following should be defined:

• Which situations require release to be placed on hold;
• Which situations are considered acceptable deviations;
• Whether reprocessing or retreatment is permitted;
• How reprocessed batches are identified;
• How out-of-specification results are investigated;
• Which original data must be provided;
• Whether resampling is required;
• Which actions require customer approval;
• How replacement, reproduction, or return will be handled.

Without prior agreement, a project can easily become trapped in disputes such as “the supplier’s test passed, but the customer’s application failed” or “the reprocessed batch meets specification, but the remaining quality risk cannot be assessed.”

Continued Monitoring Is Still Required after Commercial Supply Begins

Long-term procurement may include continued tracking of:

• Critical impurity trends;
• Application test pass rate;
• First-pass batch acceptance rate;
• Deviations and complaints;
• Difference between actual and planned lead time;
• Packaging and transportation abnormalities;
• Timeliness of change notifications;
• Investigation and issue-closure efficiency.

Supplier evaluation should not end after the first commercial batch passes. It should be updated continuously using actual delivery performance.

How to Make a Release Decision at Each Gate

To avoid moving forward when evidence is insufficient, each gate may use one of four decision states.

“Conditional Go” should not become a long-term method for bypassing validation. The outstanding conditions should define the responsible party, data requirements, and completion time.

How to Compare Custom Synthesis Quotations and Lead Times

Quotations Must Cover the Same Project Scope

Quotations from different suppliers are comparable only when the following conditions are similar:

• Product structural form;
• Specifications and critical impurity requirements;
• Testing scope;
• Sample and validation-batch requirements;
• Commercial batch scale;
• Packaging format;
• Documentation and change-management requirements;
• Trade terms and delivery location.

A lower price may result from wider specifications, fewer test items, reduced validation work, or different packaging requirements. It does not necessarily represent a cost advantage under equivalent conditions.

Separate Project Costs by Stage

Depending on the project, custom synthesis costs may be divided into:

• Route evaluation or research and development costs;
• Gram-scale sample costs;
• Method development or reference standard costs;
• Kilogram-scale development costs;
• Representative validation-batch costs;
• Commercial batch product price;
• Special testing, packaging, and transportation costs.

Clear stage-based pricing makes it easier to determine responsibility and cost when the project is modified, delayed, or discontinued.

Break Lead Time into Project Milestones

Total lead time usually includes:

1. Technical evaluation;
2. Critical raw material procurement;
3. Gram-scale sample synthesis;
4. Sample testing;
5. Customer application validation;
6. Kilogram-scale development;
7. Representative validation batch;
8. Formal testing and release;
9. Packaging and transportation.

A single final delivery date does not reveal where delays may occur. The project plan should identify the expected completion time for each stage and clarify whether specification changes, retesting, or customer feedback will affect subsequent milestones.

Eight High-Risk Signals in Custom Synthesis Projects

The project should be paused and additional validation requested if any of the following occurs:

1. The product name, CAS number, and structural formula do not correspond;
2. The sample source, route version, or batch number is not traceable;
3. The sample route differs from the commercial route, but no revalidation plan exists;
4. The supplier can report only total purity and cannot explain critical impurities;
5. The validation batch depends on laboratory operations that cannot be reproduced in commercial production;
6. The commercial manufacturing entity, site, or critical equipment is unclear;
7. No notification is provided when critical raw materials, route, purification method, or production site changes;
8. Critical commercial batch attributes are reported only as “Pass,” preventing trend comparison.

Custom Synthesis Supplier Evaluation Table

The weightings may be adjusted according to project risk. Problems such as incorrect product identity, inability to control critical impurities, untraceable sample sources, or an unclear commercial manufacturing entity should not be offset by high scores in other areas.

Ready-to-Use Custom Synthesis Procurement Checklist

Product Identity and Project Scope

• □ Full product name has been confirmed;
• □ CAS number has been checked;
• □ Structural formula has been confirmed;
• □ Molecular formula and molecular weight have been confirmed;
• □ Substitution position, stereochemical configuration, salt form, or solvate form has been confirmed;
• □ Intended application and downstream validation method have been explained;
• □ Confidentiality and intellectual property boundaries have been defined;
• □ Target quantities for gram-scale, kilogram-scale, and commercial batches have been stated;
• □ Estimated annual demand and purchasing frequency have been stated;
• □ Target delivery time has been confirmed.

Specifications and Analytical Methods

• □ Purity and assay have been clearly distinguished;
• □ Critical individual impurities have been identified;
• □ Isomer-control requirements have been confirmed;
• □ Moisture requirements have been confirmed;
• □ Residual solvent items have been confirmed;
• □ Metal, catalyst, or inorganic residue requirements have been confirmed;
• □ Appearance, color, and physical form requirements have been confirmed;
• □ Particle size, bulk density, or other application-related physical properties have been confirmed;
• □ Analytical methods and method versions have been defined;
• □ Methods can separate the target compound from critical impurities;
• □ The need for interlaboratory method comparison has been confirmed;
• □ It has been confirmed whether actual values are required for critical attributes rather than only “Pass.”

Sample and Scale-Up Validation

• □ Gram-scale sample quantity has been confirmed;
• □ Sample batch number and route version are traceable;
• □ Structural confirmation data have been obtained;
• □ Original chromatograms and impurity data have been obtained;
• □ The sample has completed real application validation;
• □ A reference sample has been retained under appropriate conditions;
• □ A kilogram-scale development plan has been defined;
• □ Critical process variables have been identified;
• □ Critical raw material sources and specifications have been confirmed;
• □ Impurity profiles of the gram-scale sample and scale-up batch have been compared;
• □ Reprocessing or repeated purification has been disclosed;
• □ Equipment and site for the representative validation batch have been confirmed;
• □ The number of consecutive batches has been determined based on risk;
• □ Commercial batch release criteria have been confirmed in writing.

Batch and Change Management

• □ The formal specification version has been confirmed;
• □ The COA template has been reviewed;
• □ The SDS has been obtained and corresponds to the actual product form;
• □ The TDS or formal specification sheet has been obtained;
• □ The scope for retaining original batch data has been agreed;
• □ Handling of deviations and out-of-specification results has been defined;
• □ Approval requirements for reprocessing or retreatment have been defined;
• □ Batch retention-sample requirements have been defined;
• □ Notification mechanisms for route, raw material, site, method, and packaging changes have been established;
• □ Conditions requiring resubmission of samples or revalidation after major changes have been defined.

Packaging, Storage, and Transportation

• □ Sample packaging and commercial packaging have been confirmed separately;
• □ Inner packaging material is compatible with the product;
• □ Unit packaging weight is suitable for actual production charging;
• □ Moisture protection, light protection, sealing, or other protective requirements have been confirmed;
• □ In-use and resealing requirements after opening have been confirmed;
• □ Storage temperature and environmental conditions have been confirmed;
• □ Transportation mode and suitability have been confirmed;
• □ Transportation labels and export documents have been confirmed;
• □ Destination and receiving conditions have been confirmed;
• □ Handling of packaging damage or transportation abnormalities has been agreed.

Price, Lead Time, and Trade Terms

• □ Research and development, sample, scale-up, and validation-batch costs have been stated separately;
• □ Commercial batch price has been linked to the agreed specification and batch size;
• □ Minimum order quantity has been confirmed;
• □ Tiered pricing and quotation validity have been confirmed;
• □ Special testing and packaging costs have been confirmed;
• □ Critical raw material procurement time has been explained;
• □ Sample, scale-up, validation, and commercial batch lead times have been stated separately;
• □ Delay risks and handling methods have been discussed;
• □ Payment terms have been confirmed;
• □ Trade terms have been confirmed;
• □ Responsibility for freight, insurance, taxes, and customs clearance has been confirmed;
• □ Replacement, reproduction, or return arrangements for nonconforming batches have been confirmed.

Project Support Available from ChemicalCell

ChemicalCell can support communication regarding structures and specifications, sample arrangements, scale-up feasibility, and commercial batch delivery conditions for custom requirements involving fine chemicals, organic intermediates, and functional raw materials.

The specific scope of support depends on the target structure, specification difficulty, analytical requirements, project scale, packaging format, and destination conditions. Before a custom project begins, the product identity, critical quality attributes, sample quantity, expected scale-up volume, and target timeline should first be confirmed.

FAQ

How Many Batches Are Normally Required to Validate a Custom Synthesis Project?

There is no fixed number applicable to all products. The number of batches should be determined according to process complexity, critical impurity risk, raw material variability, downstream validation cost, expected procurement scale, and the difficulty of changing suppliers. Higher-risk projects normally require trend evaluation across multiple consecutive batches, with the specific number defined in the project quality plan.

How Can Scale-Up Capability Be Evaluated if the Supplier Will Not Disclose the Full Synthetic Route?

Obtaining all proprietary process information is not necessary. The evaluation should focus on whether the supplier can confirm that the commercial route is consistent with the sample route, whether critical raw materials are stable, whether the main purification method is reproducible, how critical impurities are controlled, and whether changes in route, site, or raw materials will be communicated.

Is Revalidation Required if the Gram-Scale Sample and Commercial Batch Use Different Purification Methods?

The effect of the purification change on the impurity profile, residual solvents, color, moisture, and physical form should be reassessed. If the change may affect critical quality attributes or application performance, a new sample or representative validation batch should be required. The original gram-scale sample conclusion should not be applied directly.

Is Resubmission of Samples Required after Changing a Critical Raw Material Source?

If the change in critical raw material source may introduce new isomers, metals, salts, moisture, or other reactive impurities, the critical quality attributes should be compared again. Whether full validation is required depends on the degree of change, but a risk assessment and targeted testing should be completed at a minimum.

When Is It Appropriate to Fix the Commercial Batch Price?

Commercial batch pricing becomes comparable only after the product identity, formal specification, analytical methods, commercial route, target batch size, packaging, and validation requirements have been substantially defined. Locking the price too early may lead to later reductions in testing, changes in raw materials, or reduced validation work in order to maintain the quoted price.

Submit a Custom Synthesis Project Request

A custom synthesis inquiry may include the following core information:

• Product name, CAS number, and structural formula;
• Target purity, assay, and critical impurity requirements;
• Existing analytical methods or reference data;
• Required gram-scale sample quantity;
• Expected kilogram-scale and commercial batch demand;
• Packaging, destination, and target timeline;
• Required quality documentation;
• Payment and trade terms.

The more complete the information, the easier it is to evaluate route feasibility, sample arrangements, quality scale-up risks, realistic lead time, and bulk supply conditions.